Spot Trading
LCTX icon

Spot Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Spot Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,505
Closed -$22K – 2980
2016
Q3 		$22K Sell
6,505
-21,828
-77% -$60.3K ﹤0.01% 2796
2016
Q2 		$65K Buy
+28,333
New +$69.5K ﹤0.01% 2683
2015
Q4 		– Sell
-4,109
Closed -$10K – 3853
2015
Q3 		$10K Buy
+4,109
New +$10.6K ﹤0.01% 3604

Other funds holding LCTX

Broadwood Capital
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
Destination Wealth Management
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spot Trading's LCTX Position: Q4 2016 in Review

Spot Trading sold out of Lineage Cell Therapeutics (LCTX) in Q4 2016, closing a stake of 6,505 shares — an estimated $22K sold.

Spot Trading first reported a position in LCTX in Q3 2015 and held it in 3 quarters. The position peaked at $65K in Q2 2016. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • Spot Trading reported no remaining Lineage Cell Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 6,505 Lineage Cell Therapeutics shares in Q4 2016, an estimated $22K.
  • Spot Trading first reported a position in Lineage Cell Therapeutics in Q3 2015 and held it in 3 quarters.
  • Spot Trading's Lineage Cell Therapeutics position peaked at $65K in Q2 2016.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.